Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Psilocybin has been used for centuries for religious purposes; however, little is known scientifically about its long-term effects. We previously reported the effects of a double-blind study evaluating the psychological effects of a high psilocybin dose. This report presents the 14-month follow-up and examines the relationship of the follow-up results to data obtained at screening and on drug session days. Participants were 36 hallucinogen-naïve adults reporting regular participation in religious/ spiritual activities. Oral psilocybin (30 mg/70 kg) was administered on one of two or three sessions, with methylphenidate (40 mg/70 kg) administered on the other session(s). During sessions, volunteers were encouraged to close their eyes and direct their attention inward. At the 14-month follow-up, 58% and 67%, respectively, of volunteers rated the psilocybin-occasioned experience as being among the five most personally meaningful and among the five most spiritually significant experiences of their lives; 64% indicated that the experience increased well-being or life satisfaction; 58% met criteria for having had a 'complete' mystical experience. Correlation and regression analyses indicated a central role of the mystical experience assessed on the session day in the high ratings of personal meaning and spiritual significance at follow-up. Of the measures of personality, affect, quality of life and spirituality assessed across the study, only a scale measuring mystical experience showed a difference from screening. When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives.

[1]  W. Pahnke LSD and Religious Experience , 2010 .

[2]  J. Choksy Research in the Social Scientific Study of Religion , 2010 .

[3]  D. Hay The Psychology of Religion: An Empirical Approach (3rd edn.), by Bernard Spilka, Ralph W. Hood Jr., Bruce Hunsberger and Richard Gorsuch. New York: Guilford, 2003. 671pp., hbk. ISBN 9781572309012. , 2009 .

[4]  R. Griffiths,et al.  Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.

[5]  Felix Hasler,et al.  Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans , 2007, Psychopharmacology.

[6]  R. Piedmont Cross-cultural generalizability of the Spiritual Transcendence Scale to the Philippines: Spirituality as a human universal , 2007 .

[7]  R. Griffiths,et al.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance , 2006, Psychopharmacology.

[8]  Felix Hasler,et al.  Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin , 2005, Neuropsychopharmacology.

[9]  J. C’de Baca,et al.  Quantum change: ten years later. , 2004, Journal of clinical psychology.

[10]  A. Forcehimes De profundis: spiritual transformations in Alcoholics Anonymous. , 2004, Journal of clinical psychology.

[11]  Felix Hasler,et al.  Acute psychological and physiological effects of psilocybin in healthy humans : a double-blind , placebo-controlled dose – effect study , 2004 .

[12]  H. Isbell,et al.  The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide , 1964, Psychopharmacologia.

[13]  H. Isbell Comparison of the reactions induced by psilocybin and LSD-25 in man , 2004, Psychopharmacologia.

[14]  H. Isbell,et al.  Comparison of psilocin with psilocybin, mescaline and LSD-25 , 2004, Psychopharmacologia.

[15]  D. Cella,et al.  Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp) , 2002, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[16]  P. Watson,et al.  Dimensions of the Mysticism Scale: Confirming the Three‐Factor Structure in the United States and Iran , 2001 .

[17]  R. Hood,et al.  An empirical test of the unity thesis: The structure of mystical descriptors in various faith samples. , 2000 .

[18]  R. Hébert,et al.  Criterion Validity of a New Measure of Self-Actualization , 1999, Psychological reports.

[19]  R. Piedmont Does Spirituality Represent the Sixth Factor of Personality? Spiritual Transcendence and the Five-Factor Model , 1999 .

[20]  E. Gouzoulis-Mayfrank,et al.  Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study , 1999, Psychopharmacology.

[21]  J. Halpern,et al.  Do hallucinogens cause residual neuropsychological toxicity? , 1999, Drug and alcohol dependence.

[22]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[23]  M. Mangini,et al.  Treatment of alcoholism using psychedelic drugs: a review of the program of research. , 1998, Journal of psychoactive drugs.

[24]  A Dittrich,et al.  The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans , 1998, Pharmacopsychiatry.

[25]  H. D. Abraham,et al.  The Psychopharmacology of Hallucinogens , 1996, Neuropsychopharmacology.

[26]  Peter C. Hill,et al.  The psychology of religion: An empirical approach, 4th ed. , 1996 .

[27]  P. Stamets Psilocybin mushrooms of the world : an identification guide , 1996 .

[28]  R. R. Abidin Psychological Assessment Resources , 1995 .

[29]  R. Kellner,et al.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. , 1994, Archives of general psychiatry.

[30]  David Watson,et al.  The PANAS-X manual for the positive and negative affect schedule , 1994 .

[31]  P. Costa,et al.  Revised NEO Personality Inventory (NEO-PI-R) and NEO-Five-Factor Inventory (NEO-FFI) , 1992 .

[32]  R. Doblin PAHNKE'S "GOOD FRIDAY EXPERIMENT' A LONG-TERM FOLLOW-UP AND METHODOLOGICAL CRITIQUE , 1991 .

[33]  W. James Varieties of Religious Experience , 2008 .

[34]  Peter C. Hill,et al.  The psychology of religion : an empirical approach , 1986 .

[35]  J. Ott The Wondrous Mushroom: Mycolatry in Mesoamerica , 1981 .

[36]  R. Yensen,et al.  The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients , 1977 .

[37]  O. McCabe,et al.  Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. , 1973, Archives of general psychiatry.

[38]  S. Grof,et al.  LSD in the Treatment of Alcoholics , 1971 .

[39]  W. Pahnke Psychedelic drugs and mystical experience. , 1969, International psychiatry clinics.

[40]  Pahnke Wn Psychedelic drugs and mystical experience. , 1969 .

[41]  W. Richards,et al.  LSD-assisted psychotherapy with terminal cancer patients. , 1969, Current psychiatric therapies.

[42]  G. H. Litwin,et al.  REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT , 1963, The Journal of nervous and mental disease.

[43]  Hollister Le Clinical, biochemical and psychologic effects of psilocybin. , 1961 .

[44]  L. Hollister Clinical, biochemical and psychologic effects of psilocybin. , 1961, Archives internationales de pharmacodynamie et de therapie.

[45]  N. Smart,et al.  Mysticism and Philosophy. , 1963 .

[46]  C. R. Atwell,et al.  Experimental psychiatry. V. Psilocybine, a new psychotogenic drug. , 1960, The New England journal of medicine.

[47]  S. Malitz,et al.  Some observations on psilocybin, a new hallucinogen, in volunteer subjects. , 1960, Comprehensive psychiatry.

[48]  C. Smith,et al.  Use of d-lysergic acid diethylamide in the treatment of alcoholism. , 1959, Quarterly journal of studies on alcohol.